Shares of MiniMed Group tumbled 7.2% to $18.10 on August 28 as Wall Street slashed earnings forecasts days before the company's September 1 first-quarter report, signaling that even the Street's bulls are bracing for a rough quarter from the insulin pump and continuous glucose monitoring maker.
A Dramatic Profit Decline Has Investors Heading for the Exits
The numbers tell a stark story: analysts now expect MiniMed to earn just 9 cents per share, down from 35 cents a year ago — a 74% drop. Consensus revenue sits at $828.43 million, suggesting the top line isn't collapsing but that costs or pricing pressures are squeezing what the company keeps. For shareholders, the concern isn't a single weak quarter but whether this margin compression — shrinking profit on each dollar of revenue — reflects a temporary hiccup or a structural problem in the business.
Two Major Banks Are Telling Clients to Expect Less
Wells Fargo cut its price target to $22, while BofA Securities lowered its own to $20. Both targets still sit above the current price, implying some upside, but the direction of revisions matters more than the level. When analysts reduce targets before a company even reports, it often means channel checks — conversations with hospitals, distributors, and insurers — are pointing to weaker demand or reimbursement headwinds. The stock has shed roughly 11.5% from its August 21 close of $20.45, erasing over a week of gains in just days.
The Broader Market Isn't to Blame
With major indexes nearly flat this week, MiniMed's slide is almost entirely company-specific. That removes the convenient excuse of a "risk-off" environment and puts the spotlight squarely on execution. Investors are pricing in the possibility that competition in the diabetes device space — from rivals making cheaper pumps and next-generation glucose sensors — is eating into MiniMed's pricing power.
September 1 Becomes a Make-or-Break Moment
The earnings call will matter as much as the numbers. Management needs to explain whether the profit decline stems from one-time investment spending, temporary supply-chain costs, or a genuine loss of competitive ground. A revenue beat paired with weak guidance could still punish the stock further. At roughly 201 times the new forward earnings estimate of 9 cents, MiniMed's valuation leaves almost no room for disappointment — making the September 1 report the single most important catalyst for the stock this year.